You can buy or sell PLRX and other stocks, options, and ETFs commission-free!
Pliant Therapeutics, Inc. engages in the business of developing and commercializing novel therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. Pliant Therapeutics was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA. The listed name for PLRX is Pliant Therapeutics, Inc. Common Stock.
South San Francisco, California
52 Week High
52 Week Low
— per share
Expected Mar 11, After Hours